Mirtazapine in Alzheimer-associated Weight Loss

Completed

• Conditions: Alzheimer's Disease; Weight Loss; Mixed Dementia; Dementia

• Registration Number: NCT01505504
• Lead Sponsor: Brugmann University Hospital

Brief Summary

Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect.

The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).

Detailed Description

Not available

Study Timeline

• Study Start: 2004-01
• Primary Completion: 2011-11
• Study Completion: 2011-12
• Status Verified: 2012-01
• Study First Submitted: 2012-01-04
• Study First Submitted QC: 2012-01-05
• Last Update Submitted: 2012-01-05
• Study First Posted: 2012-01-06
• Last Update Posted: 2012-01-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• AD or mixed dementia
• documented weight loss
• mirtazapine 30 mg explicitly prescribed against weight loss

Exclusion Criteria

• no treatment compliance
• other causes of weight loss
• other interventions against weight loss

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
body weight	6 months

Trial Locations

Locations (1)

CHU Brugmann; 🇧🇪 Brussels, Belgium